Data Talk: Decoding Biologics for the Diagnosis and Treatment of Bullous Pemphigoid
PROGRAM CHAIR
Victoria P. Werth, MD
Professor of Dermatology
University of Pennsylvania
Philadelphia, PA
Michael Pasirstein, MD
Instructor, Emergency Medicine
Drexel College of Medicine/Hahnemann School of Medicine
Philadelphia, PA
PROGRAM OVERVIEW
The goal of this program is to enhance learners’ familiarity with the roles of key drivers of bullous pemphigoid (BP) that inform diagnosis and potential treatment targets. Learners will gain the ability to achieve a timely and accurate diagnosis of BP, including knowing how and when to refer to specialists. They will also have increased awareness of the need for improved treatment options for BP and awareness of the clinical profiles of novel treatment options for BP targeting different immune pathways.
TARGET AUDIENCE
This educational activity is intended for dermatologists, primary care providers, geriatricians, and emergency medicine physicians.
LEARNING OBJECTIVES
Upon completion of this program, attendees should be able to:
- Summarize the pathophysiology of BP relevant to diagnosis and the identification of treatment targets
- Incorporate diagnostic best practices for BP, including knowing how and when to refer to specialists, into routine clinical practice
- Assess the benefits and drawbacks associated with traditional therapies for the management of BP
- Evaluate the efficacy, safety, and tolerability findings from studies on novel BP treatment options that target different immune pathways
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.25 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
| Faculty Member | Disclosures |
| Victoria Werth, MD | Has received research funding from Pfizer, Biogen, Gilead Sciences, Corbus Pharmaceuticals, AstraZeneca, Amgen, Regeneron, CSL Behring, Bristol Myers Squibb (BMS), Horizon Therapeutics, ROME Therapeutics, Priovant Therapeutics, Ventus Therapeutics, Viela Bio Has served as a consultant for Janssen, Lilly, Pfizer, Biogen, BMS, Gilead Sciences, Amgen, Nektar Therapeutics, EMD Serono, CSL Behring, Crisalis, Viela Bio, Argenx, Kyowa Kirin, Regeneron, AstraZeneca, Abbvie, GSK, Cugene, UCB Pharma, ROME Therapeutics, Horizon Therapeutics, Merck, Sanofi, Calyx, Cabaletta Bio, Nuvig Pharmaceuticals, Takeda, Immunovant, AnaptysBio, Evommune, Innovaderm Research, Alpine Immune Sciences, Caribou Biosciences, Xencor, Ventus Therapeutics Has received royalties for developing and validating an outcome measure for cutaneous lupus (CLASI) and dermatomyositis (CDASI) |
| Edna Scwhab, MD | Has nothing to disclose |
| Michael Pasirstein, MD | Has nothing to disclose |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Shannon Mutch MS, RN, OCN, has nothing to disclose.
- M. Susan Burke, MD, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Surabhi Dangi-Garimella, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Andi Koral, MS, CMP, Program Manager for Med Learning Group, has nothing to disclose.
- Daniel Dasilva, Accreditation & Outcomes Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity.
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
Please listen to the podcast below:
RELEASED DATE: February 13, 2025
EXPIRATION DATE: February 13, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
PROGRAM CHAIR
Victoria P. Werth, MD
Professor of Dermatology
University of Pennsylvania
Philadelphia, PA
Michael Pasirstein, MD
Instructor, Emergency Medicine
Drexel College of Medicine/Hahnemann School of Medicine
Philadelphia, PA
PROGRAM OVERVIEW
The goal of this program is to enhance learners’ familiarity with the roles of key drivers of bullous pemphigoid (BP) that inform diagnosis and potential treatment targets. Learners will gain the ability to achieve a timely and accurate diagnosis of BP, including knowing how and when to refer to specialists. They will also have increased awareness of the need for improved treatment options for BP and awareness of the clinical profiles of novel treatment options for BP targeting different immune pathways.
TARGET AUDIENCE
This educational activity is intended for dermatologists, primary care providers, geriatricians, and emergency medicine physicians.
LEARNING OBJECTIVES
Upon completion of this program, attendees should be able to:
- Summarize the pathophysiology of BP relevant to diagnosis and the identification of treatment targets
- Incorporate diagnostic best practices for BP, including knowing how and when to refer to specialists, into routine clinical practice
- Assess the benefits and drawbacks associated with traditional therapies for the management of BP
- Evaluate the efficacy, safety, and tolerability findings from studies on novel BP treatment options that target different immune pathways
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.25 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
| Faculty Member | Disclosures |
| Victoria Werth, MD | Has received research funding from Pfizer, Biogen, Gilead Sciences, Corbus Pharmaceuticals, AstraZeneca, Amgen, Regeneron, CSL Behring, Bristol Myers Squibb (BMS), Horizon Therapeutics, ROME Therapeutics, Priovant Therapeutics, Ventus Therapeutics, Viela Bio Has served as a consultant for Janssen, Lilly, Pfizer, Biogen, BMS, Gilead Sciences, Amgen, Nektar Therapeutics, EMD Serono, CSL Behring, Crisalis, Viela Bio, Argenx, Kyowa Kirin, Regeneron, AstraZeneca, Abbvie, GSK, Cugene, UCB Pharma, ROME Therapeutics, Horizon Therapeutics, Merck, Sanofi, Calyx, Cabaletta Bio, Nuvig Pharmaceuticals, Takeda, Immunovant, AnaptysBio, Evommune, Innovaderm Research, Alpine Immune Sciences, Caribou Biosciences, Xencor, Ventus Therapeutics Has received royalties for developing and validating an outcome measure for cutaneous lupus (CLASI) and dermatomyositis (CDASI) |
| Edna Scwhab, MD | Has nothing to disclose |
| Michael Pasirstein, MD | Has nothing to disclose |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Shannon Mutch MS, RN, OCN, has nothing to disclose.
- M. Susan Burke, MD, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Surabhi Dangi-Garimella, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Andi Koral, MS, CMP, Program Manager for Med Learning Group, has nothing to disclose.
- Daniel Dasilva, Accreditation & Outcomes Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity.
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
Please listen to the podcast below:
RELEASED DATE: February 20, 2025
EXPIRATION DATE: February 20, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
PROGRAM CHAIR
Victoria P. Werth, MD
Professor of Dermatology
University of Pennsylvania
Philadelphia, PA
Edna Schwab, MD
Associate Professor of Clinical Medicine
Department of Veterans Affairs
Philadelphia, PA
PROGRAM OVERVIEW
The goal of this program is to enhance learners’ familiarity with the roles of key drivers of bullous pemphigoid (BP) that inform diagnosis and potential treatment targets. Learners will gain the ability to achieve a timely and accurate diagnosis of BP, including knowing how and when to refer to specialists. They will also have increased awareness of the need for improved treatment options for BP and awareness of the clinical profiles of novel treatment options for BP targeting different immune pathways.
TARGET AUDIENCE
This educational activity is intended for dermatologists, primary care providers, geriatricians, and emergency medicine physicians.
LEARNING OBJECTIVES
Upon completion of this program, attendees should be able to:
- Summarize the pathophysiology of BP relevant to diagnosis and the identification of treatment targets
- Incorporate diagnostic best practices for BP, including knowing how and when to refer to specialists, into routine clinical practice
- Assess the benefits and drawbacks associated with traditional therapies for the management of BP
- Evaluate the efficacy, safety, and tolerability findings from studies on novel BP treatment options that target different immune pathways
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.25 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
| Faculty Member | Disclosures |
| Victoria Werth, MD | Has received research funding from Pfizer, Biogen, Gilead Sciences, Corbus Pharmaceuticals, AstraZeneca, Amgen, Regeneron, CSL Behring, Bristol Myers Squibb (BMS), Horizon Therapeutics, ROME Therapeutics, Priovant Therapeutics, Ventus Therapeutics, Viela Bio Has served as a consultant for Janssen, Lilly, Pfizer, Biogen, BMS, Gilead Sciences, Amgen, Nektar Therapeutics, EMD Serono, CSL Behring, Crisalis, Viela Bio, Argenx, Kyowa Kirin, Regeneron, AstraZeneca, Abbvie, GSK, Cugene, UCB Pharma, ROME Therapeutics, Horizon Therapeutics, Merck, Sanofi, Calyx, Cabaletta Bio, Nuvig Pharmaceuticals, Takeda, Immunovant, AnaptysBio, Evommune, Innovaderm Research, Alpine Immune Sciences, Caribou Biosciences, Xencor, Ventus Therapeutics Has received royalties for developing and validating an outcome measure for cutaneous lupus (CLASI) and dermatomyositis (CDASI) |
| Edna Scwhab, MD | Has nothing to disclose |
| Michael Pasirstein, MD | Has nothing to disclose |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Shannon Mutch MS, RN, OCN, has nothing to disclose.
- M. Susan Burke, MD, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Surabhi Dangi-Garimella, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Andi Koral, MS, CMP, Program Manager for Med Learning Group, has nothing to disclose.
- Daniel Dasilva, Accreditation & Outcomes Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity.
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
Please listen to the podcast below:
RELEASED DATE: February 27, 2025
EXPIRATION DATE: February 27, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
PROGRAM CHAIR
Victoria P. Werth, MD
Professor of Dermatology
University of Pennsylvania
Philadelphia, PA
Edna Schwab, MD
Associate Professor of Clinical Medicine
Department of Veterans Affairs
Philadelphia, PA
PROGRAM OVERVIEW
The goal of this program is to enhance learners’ familiarity with the roles of key drivers of bullous pemphigoid (BP) that inform diagnosis and potential treatment targets. Learners will gain the ability to achieve a timely and accurate diagnosis of BP, including knowing how and when to refer to specialists. They will also have increased awareness of the need for improved treatment options for BP and awareness of the clinical profiles of novel treatment options for BP targeting different immune pathways.
TARGET AUDIENCE
This educational activity is intended for dermatologists, primary care providers, geriatricians, and emergency medicine physicians.
LEARNING OBJECTIVES
Upon completion of this program, attendees should be able to:
- Summarize the pathophysiology of BP relevant to diagnosis and the identification of treatment targets
- Incorporate diagnostic best practices for BP, including knowing how and when to refer to specialists, into routine clinical practice
- Assess the benefits and drawbacks associated with traditional therapies for the management of BP
- Evaluate the efficacy, safety, and tolerability findings from studies on novel BP treatment options that target different immune pathways
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.25 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
| Faculty Member | Disclosures |
| Victoria Werth, MD | Has received research funding from Pfizer, Biogen, Gilead Sciences, Corbus Pharmaceuticals, AstraZeneca, Amgen, Regeneron, CSL Behring, Bristol Myers Squibb (BMS), Horizon Therapeutics, ROME Therapeutics, Priovant Therapeutics, Ventus Therapeutics, Viela Bio Has served as a consultant for Janssen, Lilly, Pfizer, Biogen, BMS, Gilead Sciences, Amgen, Nektar Therapeutics, EMD Serono, CSL Behring, Crisalis, Viela Bio, Argenx, Kyowa Kirin, Regeneron, AstraZeneca, Abbvie, GSK, Cugene, UCB Pharma, ROME Therapeutics, Horizon Therapeutics, Merck, Sanofi, Calyx, Cabaletta Bio, Nuvig Pharmaceuticals, Takeda, Immunovant, AnaptysBio, Evommune, Innovaderm Research, Alpine Immune Sciences, Caribou Biosciences, Xencor, Ventus Therapeutics Has received royalties for developing and validating an outcome measure for cutaneous lupus (CLASI) and dermatomyositis (CDASI) |
| Edna Scwhab, MD | Has nothing to disclose |
| Michael Pasirstein, MD | Has nothing to disclose |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Shannon Mutch MS, RN, OCN, has nothing to disclose.
- M. Susan Burke, MD, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Surabhi Dangi-Garimella, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Andi Koral, MS, CMP, Program Manager for Med Learning Group, has nothing to disclose.
- Daniel Dasilva, Accreditation & Outcomes Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity.
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
Please listen to the podcast below:
RELEASED DATE: March 06, 2025
EXPIRATION DATE: March 06, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.